The enhancer regions of mammalian and avian U1 and U2 small nuclear RNA (snRNA) genes are unusual in containing the sequence GGGCGG (GC-box) immediately upstream from the sequence ATGCAAAT (octamer). We made point mutations in the human U2 snRNA enhancer and tested them for the ability to direct U2 transcription in HeLa cells, as well as for the ability to form complexes with factors present in HeLa cell nuclear extracts. We show that neither the GC-box nor the octamer alone is sufficient for enhancer activity in vivo. Mutations in the GC-box reduce the ability of enhancer DNA fragments to bind a factor (probably Spl), whereas mutations in the octamer independently reduce the ability to bind a second factor (probably nuclear factor A, NF-A). The results suggest that adjacent binding of Spl and NF-A is an important feature of some UsnRNA gene enhancers.
The stable small nuclear RNAs U1-U5 (U-snRNAs) are encoded by a special class of genes apparently transcribed by RNA polymerase II. The synthesis of these snRNAs is sensitive to low levels of a-amanitin {Jensen et al. 1979~ Murphy et al. 1982} , and the nascent snRNA transcripts are capped with a 7-methylguanosine residue, although this cap is subsequently modified to produce the 2,2,7-trimethylguanosine cap found on the mature snRNA species (Hernandez and Weiner 1986~ Mattaj 1986}. Many experiments indicate that U1 and U2 genes from a number of organisms contain at least two distinct elements that contribute to snRNA promoter activity {for review, see Dahlberg and Lund 1987) . The human IJ2 gene contains an upstream activator located near position -220 (Westin et al. 1984~ Ares et al. 1985} and a basal promoter which lies downstream of position -62 (Ares et al. 1985) . The upstream element has the formal properties of an enhancer in a HeLa cell transfection assay, stimulating transcription from the basal promoter in either orientation from upstream or downstream positions, but the element works best in the natural orientation upstream (Mangin et al. 1986) . Although the SV40 enhancer stimulates accurate initiation directed by the human U2 basal promoter (Mangin et al. 1986J, attempts to use the human U2 enhancer to stimulate transcription from the herpesvirus thymidine kinase (tk) pro1present address: Department of Biology, Thimann Laboratories, University of California, Santa Cruz, Santa Cruz, California 95064. moter in transfected HeLa ceils were not successful (M. Ares, unpubl.) .
The snRNA promoters differ from those RNA polymerase II promoters that direct mRNA synthesis. For example, U1 and U2 snRNA promoters lack the TATA or CAAT box homologies found in mRNA promoters (for review, see Serfling et al. 1985) , but share sequence homology with each other in regions of functional importance (for review, see Dahlberg and Lund 1987) . In addition, as yet undefined features of the snRNA promoter are required for correct snRNA 3' end formation, and this requirement is not fulfilled by any mRNA promoter yet tested (Hemandez and Weiner 1986~ Neuman de Vegvar et al. 1986 ). Despite these differences, certain snRNA enhancers share at least two sequence elements with some mRNA promoters and enhancers: the GGGCGG motif {GC-box) and the ATGCAAAT motif (octamer}.
The GC-box is an essential element of a number of viral and cellular promoters and binds transcription factor Spl {for review, see Kadonaga et al. 19861 . The GC-box homology {referred to either as a hexanucleotide GGGCGG or a decanucleotide G/TGGGCGGRRY) has been noted in the enhancer regions of avian and mammalian U1 and U2 promoters (Early et al. 1984~ Ares et al. 1985~ Korf and Stumph 1986~ Mangin et al. 1986 ) and can be identified in many but perhaps not all vertebrate U-snRNA promoters {Mangin et al. 1986 ). The human U2 enhancer contains a 9 out of 10 match to the decanu-cleotide GC-box consensus (positions -2 2 2 to -231; Ares et al. 1985; Mangin et al. 1986 ); however, evidence to assess the functional importance of this sequence has been lacking.
The octamer is found in immunoglobulin promoters and enhancers (Falkner and Zachau 1984; Parslow et al. 1984) and is important for cell type-specific expression of immunoglobulin genes (Bergman et al. 1984; Falkner and Zachau 1984; Mason et al. 1985) . Paradoxically, the octamer motif is also found within elements whose activity is largely independent of cell type. Functional elements of the tk promoter (Parslow et al. 1987 ) and the human histone H2B promoter ) contain the octamer, as does a functionally important region of the 8V40 72-bp repeat (Herr and Clarke 1986; Zenke et al. 1986 ), although more recent evidence suggests the activity of the SV40 octamer may be restricted to lymphoid cells (Ondek et al. 1987; Schirm et al. 1987) . In vitro, the octamer binds a ubiquitous factor called NF-A1 (formerly IgNF-A; Singh et al. 1986) many if not all cell types, as well as an additional factor (NF-A2) found only in lymphoid cells (Landolfi et al. 1986; Staudt et al. 1986) . The octamer or a close variant is also present in snRNA promoters, which are usually active independent of cell type; this octamer element resides 220-280 bp upstream of the cap site in all vertebrate U-snRNA genes so far sequenced (for review, see Dahlberg and Lund 1987) . A 4-bp deletion in the octamer of the human U2 gene abolishes U2 enhancer activity (Ares et al. 1985; Mangin et al. 1986 ) and the human U2 gene can compete with the histone H2B promoter for binding of NF-A1 (Sire and Roeder 1986) . In addition, a synthetic oligonucleotide containing an octamer sequence can partly replace the frog U2 enhancer (Mattaj et al. 1985) .
To address the functional importance of the GC-box and octamer elements in snRNA enhancers, we made point mutations in the human U2 enhancer and tested the mutants for enhancer activity in vivo and factor binding in vitro. The results demonstrate that neither the GC-box immediately upstream of the octamer nor the octamer sequence alone is sufficient for full function of the U2 enhancer, and that the minimal U2 enhancer binds two distinct factors, probably Spl and NF-A. Binding of each factor to the human U2 enhancer can occur independently in vitro because different mutations abolish the binding of only one or the other factor. Although the wild-type enhancer binds factors over a 60-bp region extending from -2 7 0 to -211, a 5' deletion to -2 4 0 (which leaves the GC-box and octamer elements intact but removes half of the protected region) appears to be as active as wild type in a transfection assay. We suggest that the interaction of Spl and NF-A is an important feature of the human U2 snRNA gene enhancer.
Results

Point mutations in the GC-box or in the octamer reduce U2 enhancer activity
Point mutations were generated in the enhancer region of a copy of the human U2 gene carrying an XbaI linker in the coding region, and cloned in pUC13 (Mangin et al. 1986 ). The sequences of the mutant enhancer regions are shown in Figure 1A . The mutants were introduced into HeLa cells by transfection, together with a ~-globin construct to normalize for variation in transfection efficiency (Mangin et al. 1986 ). Transcription was assayed by primer extension from a site downstream of the XbaI linker, so that the marked U2 RNA would produce a longer cDNA than endogenous U2 RNA (Mangin et al. 1986 ). The results (Fig. 1B) indicate that the upstream deletion to -240 (clone NE), which is common to all the mutant enhancers, does not significantly reduce enhancer activity (Fig. 1 , compare NE with dl-556). We will therefore refer to NE as a wild-type enhancer. Certain mutations that alter the GC-box without changing the octamer (Fig. 1B, lanes 51 , 9K, and 1P) reduce enhancer activity. Other mutations that change the octamer without altering the GC-box also reduce the ac-Cold Spring Harbor Laboratory Press on November 6, 2017 -Published by genesdev.cshlp.org Downloaded from tivity of the enhancer (lanes 10K, G, and 8). Two octamer mutations (lanes 4P and J) have less severe effects, but these alterations are found in naturally occurring variants of the snRNA octamer (for example, the human U1 octamer ATGCAGAT is like 4P). A triple mutation upstream of both the GC-box and the octamer has little effect on transcription (lane 4), whereas the triple mutations ND and L containing nucleotide substitutions in both the octamer and the extended decanucleotide GCbox consensus have very low activity (lanes ND and L). The complex substitution mutant 12, lacking wild-type sequences upstream of -209, has no detectable activity (lane 12). We conclude that mutations in either the GCbox or the octamer have pronounced effects on U2 enhancer activity in vivo and that neither the GC-box nor the octamer alone is sufficient for wild-type levels of U2 enhancer activity.
Point mutations alter formation of enhancer DNA-protein complexes in vitro
To determine whether the mutations had affected the ability of the enhancer to bind protein factors, we incubated labeled enhancer fragments with crude or partially purified HeLa cell nuclear extract and then separated the resulting protein-DNA complexes by native polyacrylamide gel electrophoresis (Fried and Crothers 1981; Garner and Revzin 1981) . Figure 2 shows the results of such "mobility-shift" experiments with each mutant enhancer using either crude nuclear extract ( Fig. 2A) or extract fractionated by heparin-agarose column chromatography ( Fig. 2B, C ; see Materials and methods).
The wild-type U2 enhancer NE forms at least three major complexes when incubated with crude extract (labeled C1, C2, and C3 in Fig. 2A , lane NE). Complex C1 and C2 nearly comigrate, but C1 reproducibly runs slightly ahead of C2 on this gel system. The wild-type fragment forms complex C1 with a factor in fraction II (Fig. 2B , lane NE; Fig. 2C , lane NE/FII) as well as complex G2 with a factor in fraction III (Fig. 2C, lane NE) . Mutations that alter the octamer but preserve the GCbox reduce the yield of C 1 and C3, but retain the ability to form C2 after incubation with crude extract ( Fig. 2A , lanes 4P, J, 10K, G, and 8) or with fraction III (Fig. 2C , lanes 4P, J, 10K, G, and 8). Mutations that alter sequences outside the octamer exhibit a complementary pattern of complex formation. The clearest of these is the double mutant 1P, which cannot form C2 and C3 but retains the ability to form C1 with crude extract or fraction II ( Fig. 2A -C, lanes 1P; the residual complex formed with 1P in fraction III has the mobility of C 1 and is probably due to a small amount of octamer binding factor in this fraction). Enhancer DNA fragments carrying mutations within both the GC-box and the octamer (lanes P, ND, L, and 12) do not form complexes efficiently.
Taken together, these data indicate that two distinct factors, one present in fraction II and the other in fraction III, can bind independently to the human U2 enhancer in vitro. The two factors appear to recognize different sites on the enhancer DNA, since binding of the factor in fraction II is sensitive to mutation of the octamer, whereas binding of the factor in fraction III is sensitive to changes in the GC-box. We did not recover a protein fraction able to form C3 by itself, and only those mutants able to form both C1 and C2 independently with the heparin-agarose fractions are also able to form C3 with crude extract (Fig. 2) . In addition, a mixture of fraction II and fraction III is sufficient to produce C3 with a DNA fragment containing two functional binding sites (Fig. 2D ), suggesting that C3 may represent a complex with both factors bound simultaneously to the enhancer.
The C1 complex contains NF-A bound to the U2 enhancer at the octamer
To determine whether the C1 complex contains the U2 enhancer bound to a factor with NF-A (octamer binding) specificity, we performed methylation interference experiments (Siebenlist and Gilbert 1980) using fraction II of HeLa cell nuclear extract and end-labeled DNA fragments representing the wild-type human U2 enhancer (positions -198 to -270) . After formation of complexes using fraction II protein and partially methylated DNA, separation of protein-DNA complexes on native acrylamide gels, and analysis of the bound and unbound DNA by chemical cleavage at the methylated purines, we found that the factor present in fraction II preferentially binds the subpopulation of DNA fragments not methylated at purines within the octamer (Fig. 3) . On the nontemplate strand, methylation of the N7 position of the G residue at position -219 (major groove) as well as methylation of the N3 position of the A residues at -215, -216, -217, or -221 (minor groove) interfere with formation of the protein-DNA complex C1 (Fig. 3) . Methylation of the G residue at -223, though not part of the octamer consensus, also inhibits binding. On the template strand, only methylation of the G residue at position -218 causes interference (data not shown). With the exception of the interference by 7-methylguanine at -223, the pattem of methylation interference we observe is very similar to that observed by others for the interaction of NF-A with the octamer present in the immunoglobulin promoters (Staudt et al. 1986 ) and enhancers and presumably identified sites of close approach between the factor and the enhancer DNA. We conclude that the octamer in the U2 enhancer binds to a factor (present in fraction II) similar to NF-A. In addition, the interference by methylation of the A residues at positions -215, -216, and -217 supports the idea that the factor in fraction II recognizes the octamer rather than an element related to the SV40 SPHI homology (see Zenke et al. 1986; Ondeck et al. 1987; Schirm et al. 1987) , which might overlap the human U2 octamer.
The adjacent GC-box and octamer elements can independently and simultaneously bind different factors
To determine whether both factors could bind simultaneously and to determine the binding site for the factor sensitive to mutation of the GC-box sequences upstream of the octamer, we performed DNase I protection experiments (Galas and Schmitz 1978) . The wild-type clone NE is protected from DNase I digestion by crude nuclear extract over a 30-bp region extending from 6 bp upstream of the GC-box to 6 bp downstream of the octamer, with partial protection an additional 4 bp downstream of the octamer (Fig. 4A , cf. lanes NE + and NE -). The triple mutation 8 in the octamer is only protected over a region encompassing the GC-box homology (lanes 8 + and 8 -). Conversely, the double mutation 1P in (and upstream of) the GC-box is only protected over a region encompassing the octamer {lanes 1P + and 1 P -). Taken together, these data reinforce the conclusion that the two factors can bind independently. In addition, the data suggest that both factors can bind simultaneously, although it is formally possible that the double protection represents an extremely rapid equilibrium between two
Cold Figure 3 . Methylation of purines in the U2 octamer interferes with complex formation. End-labeled and partially methylated DNA was bound to fraction II protein, and complexes were separated on native gels. After purification of the DNA from the complexes, the methylated sites present in DNA in complex C1 {lane C1} were compared to those present in free DNA {lane
C1 Fr
Fr} by cleavage at methylated purines. The sequence of the nontemplate strand surrounding the region of most obvious interference is written to the right (5' to 3', top to bottom). Purines whose methylation interferes with formation of C 1 are marked with a black square. m u t u a l l y exclusive single protections. Since the DNase I digestion time is short {60 sec), we favor the idea that both factors bind simultaneously.
In the experiments presented in Figures 1-3 , we used the NE clone {a 5' deletion to -240) as a wild-type control, since this deletion did not appear to affect enhancer function in the transfection assay {Fig. 1, compare lane NE with lane dl -556). Surprisingly, however, the region immediately upstream of -2 4 0 in the U2 gene is protected from DNase I digestion by factors in the HeLa cell extract (Fig. 4A, lanes d l -295 + and d l -295 -] . This region contains at least one and possibly three additional GC-box homologies, as well as a dyad symmetry (Fig.  4BJ which could bind additional factors. The protection of the template strand is similar to that observed in Figure 4 for the nontemplate strand {data not shown). A s u m m a r y of the DNase I protection experiments and a model for factor binding to the h u m a n U2 enhancer are presented in Figure 4B .
D i s c u s s i o n
The h u m a n U2 snRNA promoter contains an upstream enhancer {Mangin et al. 1986 ) that shares a GC-box and an octamer element {Ares et al. 1985; Mangin et al. 1986} with other U-snRNA genes {Dahlberg and Lund 1987). To test the functional importance of these sequence homologies, we determined the effects of point mutations on enhancer activity in vivo {Fig. 1) and factor binding in vitro {Figs. 2-4). The results demonstrate that both sequence elements are essential for full enhancer function in vivo and that the two elements bind distinct transcription factors independently in vitro.
The identity of the factors
One of the two factors that interact with t h e m i n i m a l h u m a n U2 enhancer in vitro resembles transcription factor Sp 1. This factor, present in fraction I11, protects a region of the U2 enhancer with strong homology to the GC-box consensus known to bind Spl {Fig. 4). Whereas the binding of Spl is influenced by the total match to the decanucleotide consensus G/TGGGCGGRRY {Jones et al. 1986; Kadonaga et al. 1986} , the sensitivity of Spl to mutation in known GC-boxes is similar to the sensitivity of the fraction 111 factor to mutations in the U2 GC-box. For example, G G G T G G is a naturally occurring variant of the core consensus Spl binding site G G G C G G {Jones et al. 1986}, and the equivalent change in the U2 enhancer has little effect on fraction III binding {Fig. 2}. Mutation of G residues at positions 3, 4, 6, and 9 of the decanucleotide consensus is detrimental to Spl binding {Jones et al. 1986}, and binding of the factor in fraction I11 to the h u m a n U2 GC-box mutants with G-to-T changes at these positions is reduced {mu-tants 1P, ND, and L; Figs. 2 and 4}. In addition, the reported elution of Spl from heparin-agarose {Briggs et al. 1986} is similar to what we observe for the factor inter- Figure 4 . DNase I protection of mutant and wild-type enhancer regions by crude nuclear extract from HeLa cells. (A) DNase I footprmting maps the binding sites of the factors. Binding conditions were identical to those used for the mobility shift, except that 2 gl of crude extract {lanes +) or BC100 buffer {lanes -) were incubated with 2 x 104 cpm of end-labeled fragment and then treated with DNase I. Lanes dl-295 contain the 251-bp AhalI-DdeI fragment from plasmid dl-295; lanes NE, 8, and lP contain the 221-bp AhalI-PvulI fragment from the corresponding plasmid clones. All fragments were labeled on the nontemplate strand by filling in the AhalI site at -116. As judged by the mobility shift assay, the conditions used drive all of the DNA into complex {not shown). The protected regions are indicated by brackets. As marker, the same fragments were partially methylated and cleaved at methylated purines (right panel, G>A). The sequence of the nontemplate strand of the U2 enhancer core (5' to 3', top to bottom} is shown to the right of the DNase I protection lanes. The nucleotides altered in the mutant 8 and 1P are indicated to the right of the G>A lanes. {B) Summary of footprinting data and model for factor interactions at the human U2 snRNA gene enhancer. (Top) Protected sequences in the wild-type clone NE {dl -240), the octamer mutant 8, and the GC-box mutant 1P are indicated by brackets. Nucleotides altered in the mutants are boxed. (Bottom) Protected sequences in the natural U2 gene {dl-295). Factors proposed to interact with the enhancer DNA {NF-A, circle; Spl, rounded square} are indicated. The protected sequences upstream of the core contain an excellent match to the GC-box consensus around position -265, as well as two weaker matches at -242 (on the opposite strand} and -253. A dyad symmetry not related to the GC-box is centered between positions -244 and -245 and is indicated by the arrows above the line. acting with the U2 GC-box. The results indicate that Spl or an Spl-like factor binds the human U2 enhancer in vitro and suggest that Sp 1 acts in vivo to stimulate U2 transcription.
The other factor that interacts with the U2 enhancer in vitro resembles NF-A. This factor, present in fraction II, protects a region of the U2 enhancer spanning the oc-U2 enhancer binds Spl and NF-A tamer homology (Fig. 4) and cannot bind when purines in the octamer are methylated (Fig. 3) . Binding of this factor is reduced by mutations in the U2 enhancer that alter the octamer sequence (Fig. 2B ). In addition, those mutations resembling natural variants of the octamer found in other snRNA gene enhancers are the least detrimental to the activity of the human U2 enhancer (Fig. 1) 
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Cold Spring Harbor Laboratory Press on November 6, 2017 -Published by genesdev.cshlp.org Downloaded from and have less severe but nonetheless detectable effects on binding of the factor (Fig. 2B) . These results indicate that NF-A, or a similar octamer-binding protein, recognizes the U2 enhancer in vitro and may act in vivo to stimulate U2 transcription.
U-snRNAs are efficiently expressed in most if not all cells, suggesting that the factors involved in U-snRNA synthesis should be present and abundant in all cell types. The transcription factor Spl and the octamer binding protein NF-A fulfill both of these criteria, and the data presented here support the idea that they are involved in snRNA transcription. However, accurate DNA-dependent in vitro transcription of vertebrate U1 or U2 genes has not yet been reported, and we are therefore unable to determine whether the factors that are responsible for enhancer binding in vitro are the same as those responsible for enhancer activity in vivo. This is an important point, since factor binding in vitro may not reflect factor function in vivo. For example, the octamer motif in immunoglobulin promoters and enhancers is thought to be an important determinant of lymphocytespecific gene expression (Bergman et al. 1984; Falkner and Zachau 1984; Mason et al. 1985) , but in vitro the immunoglobulin octamer is bound just as well by the ubiquitous octamer binding protein NF-A1 found in all cell types as by the lymphocyte-specific octamer binding protein NFA2 (Staudt et al. 1986 ). Since immunoglobulin promoters do not function in cells that contain the ubiquitous octamer binding factor, the simple presence of octamer binding activity cannot necessarily be taken as evidence of function. The implication is that the cell type-specific action of certain DNA-binding transcription factors may depend on interactions with auxiliary transcription factors that either do not themselves bind directly to DNA or bind to the DNA with a particular geometry relative to the other factors. Until we can transcribe U2 templates using purified factors, we cannot be certain that our binding assay is detecting only those functionally important components acting at the U2 enhancer in vivo.
An additional complexity is evident after comparison of our methylation interference results using the human U2 enhancer (Fig. 3) with those of Staudt et al. (1986) using immunoglobulin promoters. We observed partial interference by methylation at G -223, a position 2 bp upstream of the U2 octamer. The octamer-containing fragments of the immunoglobulin promoters used by Staudt et al. (1986) also contain a G at this position relative to the octamer, but methylation of these G residues did not interfere with octamer binding (Staudt et al. 1986) . Most immunoglobulin or snRNA octamers do not contain a G residue in this position, so it does not seem likely that octamer binding factors make G-specific contacts at this position. However, introduction of a methyl group at this nearby position might differentially affect the way that related but subtly different octamer binding proteins bind to the octamer DNA. Such differences may indicate that distinct factors, related to each other by their ability to bind the octamer sequence, may be acting at different genes. This may draw into question the use of competition experiments as a means to identify common factors and leaves open the possibility that there exists an snRNA gene-specific octamer binding protein.
Exceptional mutations
Most mutations that reduce binding of either factor to the enhancer also reduce transcription. The exceptions fall into two classes. In the first class are the octamer mutants J (ATGCAAAC) and 4P (ATGCAGAT). These mutants are only slightly defective in transcription (Fig.  1) , but neither binds NF-A in vitro as well as wild type (Fig. 2) . Likewise; the double mutant K is transcribed nearly as well as wild type but exhibits reduced ability to bind the octamer binding factor. However, in the case of mutant K, we can compare the activity of the double mutation with the activity of each of the component single mutations. Transcription of the single mutants 9K and 10K is much lower than that of the double mutant K, indicating that the double mutation has the strange but reproducible effect of restoring efficient transcription without restoring efficient octamer binding in vitro. The G-to-A change at position -230 in mutant K changes the surrounding sequence from TGTGAAAGG to TGTGAAAAG, increasing homology to the SV40 "enhancer core" consensus TGTGGAAAG, whereas the change at -211 generates ATGCAAAG, the version of the octamer present in the SV40 enhancer. Perhaps this double mutant mimics the SV40 enhancer, an element known to stimulate transcription from the U2 basal promoter (Mangin et al. 1986 ).
The second class includes the GC-box mutants 9K and 51. These mutants bind factors nearly as well as wild type in vitro, yet are much reduced in transcription. Admittedly, the in vitro binding reactions were optimized for the wild-type enhancer fragment, but we were unable to improve or reduce binding of these mutants relative to wild type by altering the conditions of the binding reaction (data not shown). One possible explanation for the anomalous behavior of mutants 9K and 51 is that the 5' deletion to -240, which is common to all the point mutants, may remove additional Spl binding sites upstream (Fig. 4) . As a result, transcription might become more sensitive to subtle mutations in the sole remaining GC-box than it would be in the natural U2 gene where the upstream Spl binding sites could partially compensate for the mutation. In fact, multiple Sp 1 binding sites are the rule in Spl-responsive promoters , lending support to the interpretation that the parental -240 construct used for mutagenesis might magnify the effects of GC-box mutations on transcription.
The existence of these exceptional mutants suggests either that the in vitro binding conditions do not effectively mimic those in vivo or that DNA binding alone is not an adequate measure of factor activity. Alternatively, since U1 and U2 3' end formation require snRNA promoter elements (Hemandez and Weiner 1986; Neuman de Vegvar et al. 1986 ), the exceptional mutants might affect formation of the 3' end of the transcript rather than initiation. Throughout this study we have used primer extension to measure accumulation of RNA initiated at the U2 cap site; thus, an enhancer mutation
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Is a protein-protein interaction between Spl and NF-A a special feature of snRNA enhancers?
Binding sites for Spl and NF-A are adjacent to each other in the human U2 enhancer as well as in other U-snRNA gene enhancers. With two exceptions, this arrangement is peculiar to U-snRNA enhancers. The tk promoter contains two essential GC-boxes (McKnight et al. 1984; Eisenberg et al. 1985 ) that bind to Spl (Jones et al. 1985) , as well as a recently identified octamer that contributes to promoter function in vivo (Parslow et al. 1987) . This octamer element is 27 bp from one of the tk GC-boxes and 75 bp from the other. The SV40 enhancer and early promoter contain an octamer-like sequence (ATG-CAAAG) positioned 29 bp from a cluster of 6 GC-boxes that bind Spl (Dynan and Tjian 1983b; Gidoni et al. 1985) , although it is not clear whether the important element is the octamer homology itself or the direct repeat of the SPHI element which fortuitously generates an octamer homology (Zenke et al. 1986; Ondek et al. 1987; Schirm et al. 1987) . In neither of these cases is the octamer immediately adjecent to a GC-box, as found in many of the U-snRNA enhancers (Mangin et al. 1986 ).
The frog U2 gene contains an enhancer-like element (Mattaj et al. 1985) that is nearly identical in sequence to the human U2 enhancer over the region where Spl and NF-A bind to the human enhancer ( Figs. 2-4 ; see Ares et al. 1985) . Thus, it is not surprising that similar DNase I protection patterns are obtained with human factors on both the wild-type human enhancer NE (Fig. 4) and frog U2 enhancer {Bohmann et al. 1987). Bohmann et al. (1987) attributed protection of the frog U2 octamer to NF-A, but did not comment on protection of the adjacent GC-box. Based on the published chromatographic behavior of Spl on DEAE-Sepharose (Dynan and Tjian 1983a) and phosphocellulose columns (Dynan and Tjian 1983b) , the fractions used by Bohmann et al. (1987) would be expected to contain most of the Sp 1 present in the starting material. Our results suggest that the protection of the frog U2 GC-box observed by Bohmann et al. (1987) resulted from Spl in their partially purified NF-A fraction and that Sp 1 is also an important factor in transcription of frog U2.
The close proximity of the binding sites for Spl and NF-A (Fig. 2) suggests that these two factors might interact with each other. Alternatively, since the two factors bind independently to the enhancer in vitro, an auxiliary factor that does not itself bind to DNA might recognize Spl and NF-A when they are bound to adjacent sites on the DNA. The ability of the frog U2 enhancer to promote the formation of stable transcription complexes in microinjected oocytes (Mattaj et al. 1985) leads us to expect that Spl and NF-A will be found to participate in the formation of stable transcription complexes at the human U2 enhancer.
Adjacent binding sites for Spl and NF-A appear to be characteristic of some but not all U-snRNA enhancers.
In other cases, Spl binding sites may be present farther from the octamer, difficult to detect because of poor match to the GC-box consensus, or perhaps replaced by binding sites for other factors. Many of the mutations that reduce transcription of U2 in human ceils also reduce binding of one or the other factor, suggesting that binding of both Spl and NF-A is important for efficient transcription of human U2. This unusual arrangement may also be responsible for some of the unique properties of these specialized RNA polymerase II promoters, such as exceedingly high rates of transcription (a minimum of one transcript/gene/2-4 sec for human U2 snRNA; Ares et al. 1985) or the ability of the RNA polymerase to recognize different 3' end formation signals downstream in the transcription unit (Hernandez and Weiner 1986; Neuman de Vegvar et al. 1986 ).
Materials and methods
Construction of point mutations
A mixed population of 32-residue oligodeoxynucleotides was synthesized which differed at random from the programmed wild-type sequence 5'-CGAATTTGCATGCCCCGCCCTTT-CACAGAGCT-3', once in every 26 residues on average. This mixed population was then phosphorylated and ligated in two steps (Derbyshire et al. 1987 ) between the AsuII site at position -211 and the SacI site of the polylinker of the marked human U2 gene carried in pUC13 (Mangin et al. 1986 ). The DNA was transformed (Hanahan 1983 ) into E. coli JM101, and plasmid DNA from clones was sequenced (Chen and Seeburg 1985) using a primer complementary to lac sequences adjacent to the polylinker (M13 17-mer, P-L Biochemicals). The single mutants 9K and 10K were derived from the double mutant K, and the double mutant 1P and single mutant 4P were derived from the triple mutant P, by using an EcoRI-SphI or SphI-XbaI fragment to replace the corresponding region of the wild-type NE clone.
Expression of U2 enhancer mutants
Transfection of U2 enhancer mutants into HeLa cells, normalization to expression of a cotransfected rabbit ~-globin gene, and primer extension using the L15 oligo were all as described previously (Mangin et al. 1986 ).
Preparation and fractionation of HeLa cell nuclear extracts
Extracts of HeLa cell nuclei were prepared according to Heintz and Roeder (1984) , dialyzed into BC100 buffer (20 mM HEPES pH 7.9, 20% glycerol, 1 mM dithiothreitol, 0.2 m/vi EDTA, and 100 mM KC1), and frozen at -70°C. Crude extract was bound to heparin-agarose {Sigma) according to Singh et al. {1986) . Material not bound at 0.1 M KC1 (flow-through, fraction I) as well as material eluting in successive step washes at 0.25 M KC1 {frac-tion II), 0.4 M KC1 (fraction III), and 0.6 M KC1 (fraction IV) were precipitated by addition of an equal volume of saturated (NH4)zSO4, resuspended in one-half the original volume of BC100 and dialyzed against BC100. Protein concentrations were estimated by spotting a dilution series of known concentration of bovine serum albumin and unknown samples onto nitrocellulose and staining with Ponceau S. Generally the protein concentration of the crude extract was 25 mg/ml, that of fraction II 2 mg/ml, and that of fraction III 2 mg/ml.
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Detection of protein-DNA complexes by gel electrophoresis
End-labeled DNA fragments were synthesized by cleaving DNA from each of the mutants with AvaI, filling the staggered ends with Klenow fragment in the presence of ~-[a2p]dCTP, and redigesting the DNA with EcoRI. Labeled enhancer DNA fragments were fractionated on native 12% polyacrylamide gels, detected by autoradiography, excised, and eluted. Crude extract (-25 ~g) or heparin-agarose fractions (-2 ~g) were incubated with 1-5,000 cpm of end-labeled DNA fragment in 11 ~1 of 0.1 M NaC1, 10 mM Tris-HC1 (pH 7.6), 1 mM dithiothreitol, 5% glycerol, 0.1 ~g/~l poly(dI-dC) (Sigma), and 2% polyvinyl alcohol with either 2.5 mM MgC12 or 1 mM EDTA as indicated. Samples were incubated at 20°C for 10 rain, 2 ~1 of a solution containing 5% Ficoll and 0.05% xylene cyanol was added, and the samples were loaded on 2-mm-thick 4% polyacrylamide (30:1, acrylamide:bis-acrylamide) gels, containing 45 mM Tris, 290 ~ glycine, 1 mM EDTA, pH 8.6-8.8. Gels were prerun 90 rain (using the above buffer), loaded, and then run 90-120 rain at constant current, starting at 6 V/cm. Gels were usually dried before autoradiography.
Methylation interference and DNase I footprinting
Methylation interference (Siebenlist and Gilbert 1980) was performed by incubating 5 x l0 s cpm of end-labeled DNA fragment with 5 ~1 (about 10 ~g} of fraction II protein in a 50-~1 reaction as above, in binding buffer containing 1 mM EDTA. After electrophoresis and autoradiography of the wet gel, bands corresponding to bound and unbound DNA were excised and eluted in 0.5 ml 500 mM Na acetate, 0.1% SDS, 1 mM EDTA at 37°C overnight. After phenol extraction and ethanol precipitation of the eluted DNA, base cleavage at methylated purines was performed as described by Falvey and Grindley (1987) , and the cleavage products were separated on a 8% polyacrylamide-8 M urea gel. Footprinting (Galas and Schmitz 1978) was performed using U2 gene fragments labeled by filling in the AhaII site at position -118 with the Klenow fragment of DNA polymerase I and recutting the DNA in upstream vector sequences with PvulI (clones NE, 1P, and 8) or DdeI (clone dl-295). Labeled fragments were incubated with crude extract (as for gel shift assays with 2.5 rnM MgC12) , and 1 ~1 of an empirically determined concentration of DNase I in BC100 buffer was added. After incubation for 60 sec at 20°C, the reaction was stopped by addition of 250 ~1 of 0.4 M LiC1, 100 mM Tris-HC1 (pH 7.4), 10 mM EDTA, 1% SDS, 10 ~g/ml E. coli tRNA, 100 ~g/ml proteinase K, incubated at 42°C for 20 min, extracted with phenol, precipitated with ethanol, and run on denaturing 6% polyacrylamide-8 M urea gels.
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Note added in proof
A recent paper describes binding results similar to those pre-
